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-Type Natriuretic Peptides
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hristian Mueller, MD, FESC
asel, Switzerland
I’ll be surprisingly good for you.
Madonna alias Evita to Juan Domingo Pero´n
in the musical Evita
n providing primary care, general practitioners (GPs) form
he backbone of health care systems in most countries. In
he last few decades we have witnessed a relentless increase
n specialization in all fields of medicine, advances in
edical technology (particularly in imaging techniques),
udgetary restrictions, and high patient expectations. As a
onsequence, most GPs now find themselves in a keenly
ompetitive situation (1). The introduction and clinical
alidation of novel laboratory tests for common diagnostic
nd prognostic challenges offer valuable help for GPs.
See page 1694
B-type natriuretic peptides (BNP) and N-terminal (NT)-
roBNP are quantitative markers of heart failure (HF),
ummarizing the extent of systolic and diastolic left ventric-
lar dysfunction, valvular dysfunction, and right ventricular
ysfunction (2,3). They have been shown to be extremely
elpful in the management of patients presenting with
yspnea to the emergency department (ED) (4). Among
D patients with dyspnea, HF is the cause in about
ne-half.
Most patients with dyspnea, however, will present to
heir GP rather than to the ED. In comparison with their
D colleagues, GPs are on the whole more experienced and
dditionally benefit from having detailed knowledge of their
atients’ past medical and personal histories. On the other
and, their access to further investigations (for example,
hest radiograph, pulse oximetry, spirometry, computed
omographic scanning, and echocardiography) and specialist
onsultation is more limited. In addition, disease severity
ay be less and mean age may be greater in patients who
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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rokus Foundation, Abbott, Biosite, Brahms, Roche, and the University of Basel.resent to their GP—2 factors that further increase the
iagnostic challenge (3).
The measurement of BNPs may, therefore, be useful for
Ps as well as ED physicians, particularly because this can
e done relatively cheaply and quickly using simple point-
f-care devices. Previous reports suggesting that the use of
NPs might be as useful for the GP as they are for the ED
hysician (5–8) are confirmed in the excellent report by
ogelvang et al. (8) in this issue of the Journal. In a
ubstudy of 959 patients reporting some degree of dyspnea
n the Fourth Copenhagen City Heart Study, plasma
roBNP concentrations were shown to be increased in left
entricular dilatation, hypertrophy, systolic dysfunction, or
iastolic dysfunction, but were unaffected by pulmonary
ysfunction.
Attention to the following 5 critical issues may help put
hese data into perspective. First, the incidence of HF as the
ause of new or worsening dyspnea in patients presenting to
heir GP is uncertain, and may vary significantly according
o the local setting. Available data suggest that HF is the
ause of dyspnea in 25% to 35% of cases (5–8). Although
his is significantly less than the 50% observed in the ED, it
ould still leave HF as the most common disorder leading
o dyspnea in the primary care setting. Second, it is crucial
o note that the identification of cardiac dysfunction using
chocardiography as the gold standard is a different matter
rom determining whether HF is the cause of dyspnea. The
atter additionally requires detailed patient history, physical
xamination, and at times additional tests (e.g., D-dimers
nd computed tomography scans to exclude or detect
ulmonary embolism). One cannot assume that all patients
ith some degree of cardiac dysfunction on echocardiogra-
hy do in fact have HF and cardiac dyspnea! Third, this
istinction leads to the conclusion that echocardiography as
stand-alone test is an appropriate gold standard for the
etection of cardiac dysfunction, but not for determining
hether HF is the underlying cause of dyspnea. For
xample, left ventricular ejection fraction as a single variable
s significantly less accurate for the diagnosis of HF as
ompared with BNP testing (5,9). On the other hand,
ecause BNPs summarize the extent of systolic and diastolic
eft ventricular dysfunction, valvular dysfunction, and right
entricular dysfunction, their correlation with left ventricu-
ar ejection fraction is only modest (10). Accordingly, BNPs
nd echocardiography should be considered complementary
ethods, each providing a different window on the heart.
ourth, diastolic dysfunction is still poorly understood and
here is considerable uncertainty surrounding its interpreta-
ion. For example, there is no consensus regarding which
itral inflow pattern constitutes normal diastolic function
n a 75-year-old person. This uncertainty is highlighted in
he current article, which reports Doppler echocardio-
raphic findings interpreted as severe diastolic dysfunction
n comparable frequency in asymptomatic individuals and in
atients with dyspnea (see Table 1 of Mogelvang et al. [8]).
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October 23, 2007:1702–3 Editorial Commentlthough tissue Doppler scanning may provide additional
nsights, this technique is often not routinely applied. When
iscussing these fundamental questions, it is important to
ear in mind that diastolic dysfunction is thought to account
or HF in about one-half of all cases. Fifth, it is currently an
nresolved question whether the use of BNPs for the
valuation of patients presenting with dyspnea to physicians
n primary care requires specific cutoff values or whether the
utoff values validated in large ED studies can be applied. In
he absence of a large observational primary care study with
edicated adjudication of the gold standard diagnosis, the
redominance of New York Heart Association functional
lass I to III patients in recent ED studies seems to justify
he use of identical cutoff values in patients presenting with
ew or worsening dyspnea (11,12), irrespective of the
etting.
Overall, there is a sound basis for GPs to measure BNPs
n patients with dyspnea. Available data suggest that BNPs
re also the single most accurate variables in the diagnosis of
yspnea in the primary care setting. In recent studies, the
rea under the receiver-operator characteristic curve for the
bility of BNPs to diagnose HF in primary care was
pproximately 0.85. Additionally, there is evidence from a
arge randomized controlled trial conducted by one of the
ost prestigious groups in this area showing that the use of
NPs significantly improves the diagnostic accuracy of HF
y GPs over and above customary clinical assessment (6).
his study included 305 patients age 40 years or older
resenting to their GPs with symptoms of dyspnea and/or
dema of recent onset. We are currently awaiting the results
f BASEL III–Private Practice (B-Type Natriuretic Pep-
ide for Acute Shortness of Breath Evaluation Study III–
rivate Practice), an international, multicenter, randomized,
ontrolled study of the impact of rapid BNP testing on
atient management and resource use in patients presenting
ith new or worsening dyspnea to doctors in private
ractice. Enrollment into the study was completed in March
007, and the results will document whether the increase in
iagnostic accuracy offered by BNPs will ultimately improve
atient outcome.
B-type natriuretic peptides are simple, rapid, inexpensive,nd accurate quantitative markers of HF. All of the currentvidence, including the data presented in this issue of the
ournal, points us toward strongly encouraging our col-
eagues in primary care to use BNPs in patients who present
ith dyspnea.
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